Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Personalis, Inc. (PSNL)
USD15.02
-0.02 (-0.13%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
1330 O’Brien Drive 94025
Fremont, CA, US
Fremont, CA, US
CEO
Christopher Hall
Website
personalis.com
IPO
2019-06-20
CIK 1527753 ISIN US71535D1063
Description
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD15.02
-0.02 (-0.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
2.24
Float Shares
52.76M
Free Float %
59.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.34% | -4.15% | -3.99% | -31.11% | -27.84% | -27.39% | +13.33% | +177.88% | -68.87% | -79.71% | -79.71% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
15.02
Low
11.00
-26.8%
Consensus
11.67
-22.3%
Median
11.00
-26.8%
High
13.00
-13.4%
DCF (Unlevered)
1.13
-92.5%
DCF (Levered)
1.04
-93.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 5 |
10.20
-32.1%
|
| All Time | 13 |
8.19
-45.5%
|
Quality scores
Altman Z-Score
1.53
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-100.0% Q1'26: -24.9% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+33.6% ★ Q1'26: -61.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%— Q1'26: -165.9% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%— Q1'26: -207.9% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-152.6% Q1'26: -244.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+50.6% Q1'26: +19.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.45× Q1'26: -0.26× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
65.21M
est: 64.89M (+0.5%)
|
78.65M
est: 78.43M (+0.3%)
|
85.49M
est: 85.32M (+0.2%)
|
65.05M
est: 65.05M (+0.0%)
|
73.48M
est: 80.03M (-8.2%)
|
84.61M
est: 84.60M (+0.0%)
|
—
est: 69.53M (-100.0%)
|
78.74M
78.70M – 78.79M
+13.3% YoY
|
111.14M
108.61M – 113.69M
+41.1% YoY
|
157.49M
156.89M – 158.08M
+41.7% YoY
|
184.10M
176.70M – 188.89M
+16.9% YoY
|
227.40M
218.25M – 233.32M
+23.5% YoY
|
| EBITDA |
-19.19M
est: -51.55M (+62.8%)
|
-35.46M
est: -33.16M (-6.9%)
|
-59.01M
est: -64.60M (+8.6%)
|
-104.64M
est: -90.62M (-15.5%)
|
-96.81M
est: -40.35M (-139.9%)
|
-70.30M
est: -42.66M (-64.8%)
|
-71.00M
est: -35.06M (-102.5%)
|
-39.70M
-39.73M – -39.68M
-13.3% YoY
|
-56.04M
-57.33M – -54.76M
-41.1% YoY
|
-79.41M
-79.71M – -79.11M
-41.7% YoY
|
-92.83M
-95.24M – -89.09M
-16.9% YoY
|
-114.66M
-117.65M – -110.05M
-23.5% YoY
|
| EBIT |
-23.94M
est: -55.09M (+56.5%)
|
-41.22M
est: -40.04M (-2.9%)
|
-65.03M
est: -71.72M (+9.3%)
|
-113.07M
est: -99.01M (-14.2%)
|
-108.10M
est: -43.55M (-148.2%)
|
-81.24M
est: -46.04M (-76.5%)
|
-81.04M
est: -37.83M (-114.2%)
|
-42.85M
-42.88M – -42.83M
-13.3% YoY
|
-60.48M
-61.86M – -59.10M
-41.1% YoY
|
-85.70M
-86.02M – -85.37M
-41.7% YoY
|
-100.18M
-102.79M – -96.15M
-16.9% YoY
|
-123.74M
-126.96M – -118.76M
-23.5% YoY
|
| Net Income |
-25.08M
est: -58.66M (+57.2%)
|
-41.28M
est: -39.22M (-5.3%)
|
-65.23M
est: -71.57M (+8.9%)
|
-113.32M
est: -110.17M (-2.9%)
|
-108.30M
est: -143.06M (+24.3%)
|
-81.28M
est: -129.25M (+37.1%)
|
-81.27M
est: -81.27M (+0.0%)
|
-92.13M
-96.13M – -88.12M
-13.4% YoY
|
-80.30M
-83.79M – -76.81M
+12.8% YoY
|
-66.04M
-68.53M – -63.55M
+17.8% YoY
|
-51.76M
-53.51M – -49.05M
+21.6% YoY
|
-41.94M
-43.36M – -39.75M
+19.0% YoY
|
| SGA |
22.08M
est: 41.43M (-46.7%)
|
33.69M
est: 32.06M (+5.1%)
|
47.70M
est: 52.56M (-9.3%)
|
63.97M
est: 60.72M (+5.3%)
|
49.73M
est: 60.24M (-17.5%)
|
46.19M
est: 63.69M (-27.5%)
|
53.57M
est: 52.34M (+2.4%)
|
59.28M
59.25M – 59.31M
+13.3% YoY
|
83.67M
81.76M – 85.58M
+41.1% YoY
|
118.55M
118.11M – 119.00M
+41.7% YoY
|
138.59M
133.01M – 142.20M
+16.9% YoY
|
171.18M
164.30M – 175.64M
+23.5% YoY
|
| EPS |
-1.39
est: -0.99 (-40.4%)
|
-1.20
est: -1.13 (-5.9%)
|
-1.49
est: -1.53 (+2.6%)
|
-2.48
est: -2.45 (-1.0%)
|
-2.25
est: -1.62 (-39.1%)
|
-1.37
est: -1.45 (+5.4%)
|
-0.91
est: -0.94 (+3.0%)
|
-1.04
-1.08 – -0.99
-11.0% YoY
|
-0.91
-0.94 – -0.86
+12.8% YoY
|
-0.74
-0.77 – -0.71
+18.5% YoY
|
-0.58
-0.60 – -0.55
+21.6% YoY
|
-0.47
-0.49 – -0.45
+19.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-117.03M
OE per share TTM
-1.24
Owner's Yield
-18.75%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
88.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
35
Total invested
65.02M
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tempus Labs, Inc. | 9.22M | 15.80% | 9.22M | — | 9.22M | — | CO | Delaware | 2023-12-05 | ↗ |
| 2 | RAVI MHATRE | 7.85M | 24.62% | — | 7.85M | — | 11.00 | IN | — | 2020-08-24 | ↗ |
| 3 | Barry Eggers | 6.08M | 19.50% | — | 6.08M | — | — | IN | United States of America | 2020-02-14 | ↗ |
| 4 | Peter Y. Nieh | 6.08M | 19.50% | — | 6.08M | — | — | IN | United States of America | 2020-02-14 | ↗ |
| 5 | Abingworth Bioventures V, LP | 4.46M | 11.60% | — | 4.46M | — | — | PN | England | 2020-08-20 | ↗ |
| 6 | Abingworth LLP | 4.46M | 11.60% | — | 4.46M | — | — | PN | England | 2020-08-20 | ↗ |
| 7 | JPMORGAN CHASE & CO.13-2624428 | 4.27M | 9.50% | 3.51M | — | 4.27M | — | HC | Delaware | 2022-01-14 | ↗ |
| 8 | Lightspeed General Partner VIII, L.P. | 4.12M | 13.20% | — | 4.12M | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 9 | Lightspeed Ultimate General Partner VIII, Ltd. | 4.12M | 13.20% | — | 4.12M | — | — | OO | Cayman Islands | 2020-02-14 | ↗ |
| 10 | Lightspeed Venture Partners VIII, L.P. | 4.12M | 13.20% | — | 4.12M | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 11 | LIGHTSPEED ULTIMATE GENERAL PARTNER VIII, LTD. | 4.12M | 12.91% | — | 4.12M | — | 11.00 | OO | — | 2020-08-24 | ↗ |
| 12 | ARK Investment Management LLC | 3.95M | 10.01% | 3.95M | — | 3.95M | — | IA | Delaware, United States | 2020-11-10 | ↗ |
| 13 | JEREMY LIEW | 3.73M | 11.71% | — | 3.73M | — | 11.00 | IN | — | 2020-08-24 | ↗ |
| 14 | 27-4413262 | 3.00M | 5.80% | 3.00M | — | 3.00M | — | OO | Maryland | 2024-07-26 | ↗ |
| 15 | Identification Nos. of above persons (. | 3.00M | 5.80% | 3.00M | — | 3.00M | — | IN | States | 2024-07-26 | ↗ |
| 16 | (1) BlackRock, Inc. | 2.92M | 5.10% | — | 2.59M | 2.92M | — | HC | Delaware | 2024-11-08 | ↗ |
| 17 | Lightspeed General Partner Select, L.P. | 1.96M | 6.30% | — | 1.96M | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 18 | Lightspeed Ultimate General Partner Select, Ltd. | 1.96M | 6.30% | — | 1.96M | — | — | OO | Cayman Islands | 2020-02-14 | ↗ |
| 19 | Lightspeed Venture Partners Select, L.P. | 1.96M | 6.30% | — | 1.96M | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 20 | LIGHTSPEED ULTIMATE GENERAL PARTNER SELECT, LTD. | 1.96M | 6.14% | — | 1.96M | — | 11.00 | OO | — | 2020-08-24 | ↗ |
| 21 | ARIF JANMOHAMED | 1.77M | 5.56% | — | 1.77M | — | 11.00 | IN | — | 2020-08-24 | ↗ |
| 22 | LIGHTSPEED GENERAL PARTNER SELECT IV, L.P. | 1.77M | 5.56% | — | 1.77M | — | 11.00 | PN | — | 2020-08-24 | ↗ |
| 23 | LIGHTSPEED ULTIMATE GENERAL PARTNER SELECT IV, L.L.C. | 1.77M | 5.56% | — | 1.77M | — | 11.00 | OO | — | 2020-08-24 | ↗ |
| 24 | LIGHTSPEED VENTURE PARTNERS SELECT IV, L.P. | 1.77M | 5.56% | — | 1.77M | — | 11.00 | PN | — | 2020-08-24 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
35
-96 vs prev Q
New positions
4
Closed positions
94
Increased
13
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 290.0K +290.0K (+100.0%) | 2.31B +2.3B (+100.0%) | 0.33% +0.327 pp | 1.97% +1.970 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 2 | MERCK & CO., INC. | 14.04M +— (+0.0%) | 111.80M +20.2M (+22.1%) | 15.83% -0.033 pp | 40.47% +0.308 pp | USD5.78 +37.7% | 5 qtrs — |
| 3 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 10.78M +7.9M (+273.9%) | 85.81M +67.0M (+356.4%) | 12.15% +8.896 pp | 0.05% +0.043 pp | USD7.58 +5.0% | 3 qtrs — |
| 4 | LIGHTSPEED MANAGEMENT COMPANY, L.L.C. | 8.16M +— (+0.0%) | 64.96M +11.8M (+22.1%) | 9.20% -0.019 pp | 4.65% -11.874 pp | USD5.78 +37.7% | 5 qtrs — |
| 5 | ARK INVESTMENT MANAGEMENT LLC | 7.88M -31.1K (-0.4%) | 62.72M +11.1M (+21.6%) | 8.88% -0.053 pp | 0.42% +0.109 pp | USD15.84 -49.7% | 27 qtrs — |
| 6 | AMERIPRISE FINANCIAL INC | 6.29M +6.0M (+2,002.6%) | 50.05M +48.1M (+2,466.9%) | 7.09% +6.750 pp | 0.01% +0.011 pp | USD7.88 +1.0% | 27 qtrs — |
| 7 | BLACKROCK, INC. | 5.32M -325.3K (-5.8%) | 42.34M +5.5M (+15.1%) | 6.00% -0.380 pp | 0.00% +0.000 pp | USD5.92 +34.5% | 6 qtrs — |
| 8 | VANGUARD GROUP INC | 3.25M +247.4K (+8.2%) | 25.90M +6.3M (+32.1%) | 3.67% +0.272 pp | 0.00% +0.000 pp | USD10.58 -24.8% | 27 qtrs — |
| 9 | ABRDN PLC | 3.25M +861.9K (+36.1%) | 25.87M +10.3M (+66.2%) | 3.66% +0.966 pp | 0.04% +0.015 pp | USD5.53 +43.9% | 5 qtrs — |
| 10 | AIGH CAPITAL MANAGEMENT LLC | 2.90M -992.1K (-25.5%) | 23.08M -2.3M (-9.0%) | 3.27% -1.128 pp | 5.59% -1.564 pp | USD5.35 +48.8% | 6 qtrs — |
| 11 | KENNEDY CAPITAL MANAGEMENT LLC | 1.71M -222.4K (-11.5%) | 13.63M +1.0M (+8.1%) | 1.93% -0.255 pp | 0.29% +0.010 pp | USD5.58 +42.7% | 4 qtrs — |
| 12 | BLUE WATER LIFE SCIENCE ADVISORS, LP | 1.68M +— (+0.0%) | 13.34M +2.4M (+22.1%) | 1.89% -0.004 pp | 8.37% -1.597 pp | USD5.72 +39.2% | 6 qtrs — |
| 13 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.45M +1.3M (+1,332.2%) | 11.53M +10.9M (+1,647.1%) | 1.63% +1.519 pp | 0.00% +0.001 pp | USD7.75 +2.7% | 17 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.30M -35.7K (-2.7%) | 10.33M +1.6M (+18.8%) | 1.46% -0.043 pp | 0.00% +0.000 pp | USD9.43 -15.6% | 26 qtrs — |
| 15 | STATE STREET CORP | 1.05M +124.2K (+13.4%) | 8.36M +2.3M (+38.5%) | 1.18% +0.138 pp | 0.00% +0.000 pp | USD7.87 +1.1% | 26 qtrs — |
| 16 | DIMENSIONAL FUND ADVISORS LP | 983.2K +9.5K (+1.0%) | 7.83M +1.5M (+23.3%) | 1.11% +0.009 pp | 0.00% +0.000 pp | USD5.65 +40.9% | 21 qtrs — |
| 17 | PFM HEALTH SCIENCES, LP | 805.8K +805.8K (+100.0%) | 6.41M +6.4M (+100.0%) | 0.91% +0.909 pp | 0.64% +0.640 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 18 | NEXT CENTURY GROWTH INVESTORS LLC | 624.4K +624.4K (+100.0%) | 4.97M +5.0M (+100.0%) | 0.70% +0.704 pp | 0.35% +0.345 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 19 | HOWLAND CAPITAL MANAGEMENT LLC | 547.1K +216.4K (+65.5%) | 4.36M +2.2M (+102.0%) | 0.62% +0.243 pp | 0.17% +0.084 pp | USD4.57 +74.2% | 14 qtrs — |
| 20 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 518.4K -72.6K (-12.3%) | 4.13M +273.5K (+7.1%) | 0.58% -0.083 pp | 0.00% +0.000 pp | USD15.28 -47.9% | 26 qtrs — |
| 21 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 518.4K -72.6K (-12.3%) | 4.13M +273.5K (+7.1%) | 0.58% -0.083 pp | 0.05% +0.010 pp | USD15.36 -48.2% | 26 qtrs — |
| 22 | STATE OF MICHIGAN RETIREMENT SYSTEM | 493.8K +— (+0.0%) | 3.93M +711.1K (+22.1%) | 0.56% -0.001 pp | 0.02% +0.004 pp | USD32.08 -75.2% | 21 qtrs — |
| 23 | PORTOLAN CAPITAL MANAGEMENT, LLC | 379.2K +379.2K (+100.0%) | 3.02M +3.0M (+100.0%) | 0.43% +0.428 pp | 0.16% +0.162 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 24 | FIRST MANHATTAN CO. LLC. | 373.8K +373.8K (+100.0%) | 2.98M +3.0M (+100.0%) | 0.42% +0.421 pp | 0.01% +0.008 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 25 | NORTHERN TRUST CORP | 354.9K -38.9K (-9.9%) | 2.83M +257.7K (+10.0%) | 0.40% -0.045 pp | 0.00% +0.000 pp | USD7.28 +9.3% | 27 qtrs — |
| 26 | GOLDMAN SACHS GROUP INC | 342.5K -231.5K (-40.3%) | 2.73M -1.0M (-27.2%) | 0.39% -0.262 pp | 0.00% 0.000 pp | USD6.14 +29.6% | 27 qtrs — |
| 27 | WELLINGTON SHIELDS CAPITAL MANAGEMENT, LLC | 340.0K +47.9K (+16.4%) | 2.71M +801.7K (+42.1%) | 0.38% +0.053 pp | 0.39% +0.106 pp | USD16.78 -52.6% | 27 qtrs — |
| 28 | ORACLE INVESTMENT MANAGEMENT INC | 339.3K +109.9K (+47.9%) | 2.70M +1.2M (+80.6%) | 0.38% +0.123 pp | 1.61% +0.674 pp | USD6.99 +13.9% | 2 qtrs — |
| 29 | NUVEEN, LLC | 308.7K +— (+0.0%) | 2.46M +444.5K (+22.1%) | 0.35% -0.001 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 30 | UBS GROUP AG | 306.6K +11.0K (+3.7%) | 2.44M +513.2K (+26.6%) | 0.35% +0.012 pp | 0.00% +0.000 pp | USD6.34 +25.6% | 26 qtrs — |
| 31 | WELLINGTON SHIELDS & CO., LLC | 292.5K +— (+0.0%) | 2.33M +421.2K (+22.1%) | 0.33% -0.001 pp | 0.57% +0.077 pp | USD8.86 -10.2% | 27 qtrs — |
| 32 | TD ASSET MANAGEMENT INC | 271.9K +217.3K (+398.1%) | 2.16M +1.8M (+508.1%) | 0.31% +0.245 pp | 0.00% +0.002 pp | USD7.67 +3.8% | 2 qtrs — |
| 33 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 267.7K +82.6K (+44.7%) | 2.13M +924.3K (+76.6%) | 0.30% +0.093 pp | 0.15% +0.065 pp | USD6.37 +25.0% | 7 qtrs — |
| 34 | PERKINS CAPITAL MANAGEMENT INC | 239.0K -13.5K (-5.3%) | 1.90M +256.1K (+15.6%) | 0.27% -0.016 pp | 1.51% +0.060 pp | USD1.20 +563.3% | 7 qtrs — |
| 35 | BRUCE & CO., INC. | 233.0K -20.0K (-7.9%) | 1.85M +205.1K (+12.4%) | 0.26% -0.023 pp | 0.58% +0.064 pp | USD2.30 +246.1% | 13 qtrs — |
| 36 | MORGAN STANLEY | 224.6K -117.5K (-34.3%) | 1.79M -442.7K (-19.8%) | 0.25% -0.133 pp | 0.00% +0.000 pp | USD4.96 +60.5% | 27 qtrs — |
| 37 | JANE STREET GROUP, LLC | 171.2K +171.2K (+100.0%) | 1.36M +1.4M (+100.0%) | 0.19% +0.193 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 38 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 158.2K +28.0 (+0.0%) | 1.26M +227.9K (+22.1%) | 0.18% 0.000 pp | 0.00% +0.000 pp | USD5.90 +34.9% | 26 qtrs — |
| 39 | D.A. DAVIDSON & CO. | 145.5K +145.5K (+100.0%) | 1.16M +1.2M (+100.0%) | 0.16% +0.164 pp | 0.01% +0.007 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 40 | WILLIAMS JONES WEALTH MANAGEMENT, LLC. | 134.1K +— (+0.0%) | 1.07M +193.1K (+22.1%) | 0.15% 0.000 pp | 0.01% +0.002 pp | USD5.73 +38.9% | 6 qtrs — |
| 41 | LPL FINANCIAL LLC | 132.3K -1.7K (-1.3%) | 1.05M +179.2K (+20.5%) | 0.15% -0.002 pp | 0.00% +0.000 pp | USD2.95 +169.8% | 16 qtrs — |
| 42 | BANK OF NEW YORK MELLON CORP | 123.0K -2.4K (-1.9%) | 978.7K +161.7K (+19.8%) | 0.14% -0.003 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 43 | BARCLAYS PLC | 120.0K +54.5K (+83.2%) | 954.8K +602.6K (+171.1%) | 0.14% +0.061 pp | 0.00% +0.000 pp | USD7.21 +10.4% | 26 qtrs — |
| 44 | AMERICAN CENTURY COMPANIES INC | 114.0K +2.0K (+1.8%) | 907.4K +177.1K (+24.3%) | 0.13% +0.002 pp | 0.00% +0.000 pp | USD5.69 +39.9% | 6 qtrs — |
| 45 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 109.0K +— (+0.0%) | 867.3K +156.9K (+22.1%) | 0.12% 0.000 pp | 0.03% +0.002 pp | USD4.06 +96.1% | 5 qtrs — |
| 46 | HRT FINANCIAL LP | 97.8K +97.8K (+100.0%) | 778.0K +778.0K (+100.0%) | 0.11% +0.110 pp | 0.00% +0.003 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 47 | RENAISSANCE TECHNOLOGIES LLC | 93.0K -360.0K (-79.5%) | 740.2K -2.2M (-74.9%) | 0.10% -0.407 pp | 0.00% -0.003 pp | USD2.74 +190.5% | 22 qtrs — |
| 48 | CITADEL ADVISORS LLC | 92.2K +92.2K (+100.0%) | 733.6K +733.6K (+100.0%) | 0.10% +0.104 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 49 | ROYAL BANK OF CANADA | 79.3K -75.1K (-48.6%) | 631.0K -375.0K (-37.3%) | 0.09% -0.085 pp | 0.00% 0.000 pp | USD6.83 +16.5% | 25 qtrs — |
| 50 | GREEN ALPHA ADVISORS, LLC | 68.5K +40.1K (+141.3%) | 545.4K +360.3K (+194.6%) | 0.08% +0.045 pp | 0.50% +0.321 pp | USD6.46 +23.2% | 19 qtrs — |
| 51 | WELLS FARGO & COMPANY/MN | 64.3K +17.3K (+36.9%) | 511.4K +205.5K (+67.1%) | 0.07% +0.019 pp | 0.00% +0.000 pp | USD6.92 +15.0% | 27 qtrs — |
| 52 | RHUMBLINE ADVISERS | 64.2K -9.9K (-13.4%) | 510.9K +27.6K (+5.7%) | 0.07% -0.011 pp | 0.00% +0.000 pp | USD6.34 +25.6% | 11 qtrs — |
| 53 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 61.8K +— (+0.0%) | 492.3K +89.1K (+22.1%) | 0.07% 0.000 pp | 0.01% +0.001 pp | USD5.50 +44.7% | 4 qtrs — |
| 54 | BANK OF AMERICA CORP /DE/ | 60.0K +26.1K (+77.1%) | 477.9K +256.8K (+116.2%) | 0.07% +0.029 pp | 0.00% +0.000 pp | USD6.75 +17.9% | 27 qtrs — |
| 55 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 56.8K -7.8K (-12.1%) | 452.4K +30.8K (+7.3%) | 0.06% -0.009 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 56 | SEI INVESTMENTS CO | 56.0K +56.0K (+100.0%) | 445.8K +445.8K (+100.0%) | 0.06% +0.063 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 57 | VERITION FUND MANAGEMENT LLC | 51.8K +51.8K (+100.0%) | 412.4K +412.4K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.002 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 58 | POLEN CAPITAL MANAGEMENT LLC | 50.7K +50.7K (+100.0%) | 403.6K +403.6K (+100.0%) | 0.06% +0.057 pp | 0.00% +0.002 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 59 | ALPHACENTRIC ADVISORS LLC | 47.8K +47.8K (+100.0%) | 380.5K +380.5K (+100.0%) | 0.05% +0.054 pp | 0.38% +0.379 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 60 | SG AMERICAS SECURITIES, LLC | 44.7K +44.7K (+100.0%) | 356.0K +356.0K (+100.0%) | 0.05% +0.050 pp | 0.00% +0.001 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 61 | INVESCO LTD. | 39.9K -338.0 (-0.8%) | 317.4K +55.2K (+21.1%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD6.29 +26.6% | 5 qtrs — |
| 62 | XTX TOPCO LTD | 39.4K -43.3K (-52.3%) | 313.7K -225.5K (-41.8%) | 0.04% -0.049 pp | 0.01% -0.020 pp | USD6.52 +22.1% | 9 qtrs — |
| 63 | PATHSTONE HOLDINGS, LLC | 39.0K +39.0K (+100.0%) | 310.6K +310.6K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.001 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 64 | DEUTSCHE BANK AG\ | 38.8K +1.7K (+4.5%) | 309.1K +66.7K (+27.5%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD6.62 +20.2% | 3 qtrs — |
| 65 | TWO SIGMA INVESTMENTS, LP | 32.5K -24.3K (-42.8%) | 258.5K -111.6K (-30.1%) | 0.04% -0.028 pp | 0.00% 0.000 pp | USD5.57 +42.9% | 6 qtrs — |
| 66 | JANNEY MONTGOMERY SCOTT LLC | 30.0K +5.0K (+20.0%) | 239.0K +76.0K (+46.6%) | 0.03% +0.006 pp | 0.00% +0.000 pp | USD6.76 +17.8% | 2 qtrs — |
| 67 | ALLIANCEBERNSTEIN L.P. | 28.7K +— (+0.0%) | 228.5K +41.3K (+22.1%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 68 | CITIGROUP INC | 27.6K +25.3K (+1,105.6%) | 219.8K +204.8K (+1,371.8%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD7.84 +1.5% | 8 qtrs — |
| 69 | JPMORGAN CHASE & CO | 26.7K +1.9K (+7.6%) | 212.7K +50.7K (+31.3%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD6.61 +20.4% | 27 qtrs — |
| 70 | INTECH INVESTMENT MANAGEMENT LLC | 20.3K +3.9K (+23.4%) | 161.9K +54.4K (+50.6%) | 0.02% +0.004 pp | 0.00% +0.001 pp | USD6.82 +16.7% | 3 qtrs — |
| 71 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 20.3K -13.7K (-40.3%) | 161.6K -60.1K (-27.1%) | 0.02% -0.016 pp | 0.00% +0.000 pp | USD5.07 +57.0% | 6 qtrs — |
| 72 | US BANCORP \DE\ | 20.1K +20.1K (+100.0%) | 159.7K +159.7K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 8 qtrs — |
| 73 | METLIFE INVESTMENT MANAGEMENT, LLC | 18.7K -11.1K (-37.4%) | 148.5K -45.7K (-23.5%) | 0.02% -0.013 pp | 0.00% 0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 74 | NEW YORK STATE COMMON RETIREMENT FUND | 15.8K +— (+0.0%) | 125.8K +22.8K (+22.1%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 75 | CREATIVE PLANNING | 15.8K +3.2K (+25.6%) | 125.5K +43.6K (+53.3%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD6.81 +16.9% | 2 qtrs — |
| 76 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 15.7K -1.7K (-9.8%) | 125.3K +11.6K (+10.2%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 77 | AXQ CAPITAL, LP | 15.0K +15.0K (+100.0%) | 119.1K +119.1K (+100.0%) | 0.02% +0.017 pp | 0.03% +0.027 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 78 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 14.5K -1.1K (-6.9%) | 115.2K +13.8K (+13.7%) | 0.02% -0.001 pp | 0.01% +0.001 pp | USD5.43 +46.6% | 5 qtrs — |
| 79 | STIFEL FINANCIAL CORP | 13.9K -34.1K (-71.0%) | 110.9K -202.1K (-64.6%) | 0.02% -0.039 pp | 0.00% 0.000 pp | USD3.42 +132.7% | 7 qtrs — |
| 80 | GUGGENHEIM CAPITAL LLC | 13.6K +13.6K (+100.0%) | 108.1K +108.1K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.001 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 81 | COLONY GROUP, LLC | 13.5K +— (+0.0%) | 107.7K +19.5K (+22.1%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD5.38 +48.0% | 6 qtrs — |
| 82 | BNP PARIBAS ARBITRAGE, SNC | 13.5K -1.3K (-9.1%) | 107.1K +10.6K (+11.0%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD6.47 +23.0% | 26 qtrs — |
| 83 | PROSHARE ADVISORS LLC | 13.1K +1.3K (+11.5%) | 104.1K +27.6K (+36.1%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD6.70 +18.8% | 3 qtrs — |
| 84 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 13.0K +— (+0.0%) | 103.3K +18.7K (+22.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
| 85 | SCIENTECH RESEARCH LLC | 12.4K +12.4K (+100.0%) | 98.7K +98.7K (+100.0%) | 0.01% +0.014 pp | 0.06% +0.062 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 86 | SKOPOS LABS, INC. | 12.0K -98.8K (-89.1%) | 95.5K -627.4K (-86.8%) | 0.01% -0.112 pp | 0.00% -0.074 pp | USD6.52 +22.1% | 2 qtrs — |
| 87 | RAYMOND JAMES FINANCIAL INC | 11.6K +— (+0.0%) | 92.3K +16.7K (+22.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD5.84 +36.3% | 5 qtrs — |
| 88 | SIMPLEX TRADING, LLC | 10.9K +4.8K (+79.8%) | 86.9K +47.9K (+122.9%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD7.16 +11.2% | 2 qtrs — |
| 89 | HSBC HOLDINGS PLC | 10.5K -41.0K (-79.6%) | 84.1K -235.9K (-73.7%) | 0.01% -0.046 pp | 0.00% 0.000 pp | USD6.27 +27.0% | 17 qtrs — |
| 90 | DRW SECURITIES, LLC | 10.5K +10.5K (+100.0%) | 83.4K +83.4K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.002 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 91 | AQR CAPITAL MANAGEMENT LLC | 10.2K +10.2K (+100.0%) | 81.5K +81.5K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 92 | ADVISOR GROUP HOLDINGS, INC. | 6.5K +1.5K (+28.7%) | 51.7K +25.4K (+96.6%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD7.99 -0.4% | 24 qtrs — |
| 93 | QUEST PARTNERS LLC | 5.0K +5.0K (+100.0%) | 39.9K +39.9K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.002 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 94 | LEGAL & GENERAL GROUP PLC | 4.6K +— (+0.0%) | 36.4K +6.6K (+22.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD6.56 +21.3% | 3 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
6.50
Bullish
Ratio by volume
3.00
Bullish
Buys
13
Sells
2
Shares acquired
1.45M
Shares disposed
2.4K
Cash buys
—
Cash sales
1.00
Net activity
+1,448,590
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-15 | Tachibana Aaron | Officer | A-Award | A | Stock Option (right to buy) | 206,250 | 6.72 | 1.39M | 206,250 | D | ↗ |
| 2026-03-15 | Moore Stephen Michael | Officer | A-Award | A | Stock Option (right to buy) | 168,750 | 6.72 | 1.13M | 168,750 | D | ↗ |
| 2026-03-15 | Hall Christopher M | Director / Officer | A-Award | A | Stock Option (right to buy) | 525,000 | 6.72 | 3.53M | 525,000 | D | ↗ |
| 2026-03-15 | Chen Richard | Officer | A-Award | A | Stock Option (right to buy) | 281,250 | 6.72 | 1.89M | 281,250 | D | ↗ |
| 2026-02-23 | Tachibana Aaron | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 1.61 | 24.2K | 15,000 | D | ↗ |
| 2026-02-23 | Moore Stephen Michael | Officer | A-Award | A | Stock Option (right to buy) | 8,333 | 1.61 | 13.4K | 8,333 | D | ↗ |
| 2026-02-23 | Hall Christopher M | Director / Officer | A-Award | A | Stock Option (right to buy) | 33,333 | 1.61 | 53.7K | 33,333 | D | ↗ |
| 2026-02-23 | Chen Richard | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 1.61 | 24.2K | 15,000 | D | ↗ |
| 2026-01-22 | Tachibana Aaron | Officer | M-Exempt | A | Common Stock | 1,201 | 9.16 | 11.0K | 165,659 | D | ↗ |
| 2025-12-22 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 28,000 | 8.93 | 250.0K | 13,039,067 | D | ↗ |
| 2025-12-19 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 29,641 | 8.39 | 248.7K | 13,011,067 | D | ↗ |
| 2025-12-18 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 31,430 | 7.91 | 248.6K | 12,981,426 | D | ↗ |
| 2025-12-17 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 31,650 | 7.86 | 248.8K | 12,949,996 | D | ↗ |
| 2025-11-25 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 9,712 | 10.08 | 97.9K | 12,904,458 | D | ↗ |
| 2025-11-25 | Tachibana Aaron | Officer | M-Exempt | D | Stock Option (right to buy) | 103,668 | 9.16 | 949.6K | 108,832 | D | ↗ |
| 2025-11-24 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 25,225 | 9.87 | 249.0K | 12,894,746 | D | ↗ |
| 2025-11-21 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 9,900 | 8.84 | 87.5K | 12,852,922 | D | ↗ |
| 2025-11-20 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 28,827 | 8.63 | 248.8K | 12,843,022 | D | ↗ |
| 2025-11-19 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 30,645 | 8.12 | 248.8K | 12,814,195 | D | ↗ |
| 2025-11-18 | Tempus AI, Inc. | 10% Owner | P-Purchase | A | Common Stock | 64,750 | 7.67 | 496.6K | 12,783,550 | D | ↗ |
| 2025-11-03 | Hall Christopher M | Director / Officer | S-Sale | D | Common Stock | 29,612 | 8.99 | 266.2K | 148,486 | D | ↗ |
| 2025-07-28 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 641 | 6.57 | 4.2K | 164,458 | D | ↗ |
| 2025-07-28 | Chen Richard | Officer | S-Sale | D | Common Stock | 452 | 6.57 | 3.0K | 124,505 | D | ↗ |
| 2025-05-16 | WIDDER KENNETH J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 4.95 | 247.5K | 50,000 | D | ↗ |
| 2025-05-16 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,291 | 4.95 | 6.4K | 165,099 | D | ↗ |
| 2025-05-16 | Shoff Lonnie | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 4.95 | 247.5K | 50,000 | D | ↗ |
| 2025-05-16 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,675 | 4.95 | 8.3K | 64,200 | D | ↗ |
| 2025-05-16 | MYERS WOODROW A JR | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 4.95 | 247.5K | 50,000 | D | ↗ |
| 2025-05-16 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 4.95 | 247.5K | 50,000 | D | ↗ |
| 2025-05-16 | Chen Richard | Officer | S-Sale | D | Common Stock | 910 | 4.95 | 4.5K | 124,957 | D | ↗ |
| 2025-05-16 | Bloom Olivia Kyusuk | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 4.95 | 247.5K | 50,000 | D | ↗ |
| 2025-05-16 | BOWMAN A BLAINE | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 4.95 | 247.5K | 50,000 | D | ↗ |
| 2025-03-15 | Tachibana Aaron | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 3.63 | 907.5K | 250,000 | D | ↗ |
| 2025-03-15 | Moore Stephen Michael | Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 3.63 | 816.8K | 225,000 | D | ↗ |
| 2025-03-15 | Hall Christopher M | Director / Officer | A-Award | A | Stock Option (right to buy) | 680,000 | 3.63 | 2.47M | 680,000 | D | ↗ |
| 2025-03-15 | Chen Richard | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 3.63 | 907.5K | 250,000 | D | ↗ |
| 2025-01-28 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 708 | 5.79 | 4.1K | 166,390 | D | ↗ |
| 2025-01-28 | Chen Richard | Officer | S-Sale | D | Common Stock | 519 | 5.79 | 3.0K | 123,367 | D | ↗ |
| 2024-12-19 | Merck & Co., Inc. | 10% Owner | — | — | Common Stock, $0.0001 par value per share | 0 | 0.00 | — | 14,044,943 | I | ↗ |
| 2024-12-16 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 6,865 | 3.82 | 26.2K | 167,098 | D | ↗ |
| 2024-12-16 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,513 | 3.82 | 5.8K | 65,875 | D | ↗ |
| 2024-12-16 | Chen Richard | Officer | S-Sale | D | Common Stock | 4,834 | 3.82 | 18.5K | 123,886 | D | ↗ |
| 2024-11-18 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,307 | 3.79 | 5.0K | 173,963 | D | ↗ |
| 2024-11-18 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,693 | 3.79 | 6.4K | 67,388 | D | ↗ |
| 2024-11-18 | Chen Richard | Officer | S-Sale | D | Common Stock | 921 | 3.79 | 3.5K | 128,720 | D | ↗ |
| 2024-11-01 | Hall Christopher M | Director / Officer | S-Sale | D | Common Stock | 26,443 | 5.38 | 142.3K | 178,098 | D | ↗ |
| 2024-08-16 | Tempus AI, Inc. | 10% Owner | X-InTheMoney | A | Common Stock | 4,609,400 | 1.50 | 6.91M | 4,609,400 | — | ↗ |
| 2024-07-30 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 742 | 2.97 | 2.2K | 175,270 | — | ↗ |
| 2024-07-30 | Chen Richard | Officer | S-Sale | D | Common Stock | 524 | 2.97 | 1.6K | 127,227 | — | ↗ |
| 2024-06-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 7,176 | 1.29 | 9.3K | 176,012 | — | ↗ |
| 2024-06-17 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,585 | 1.29 | 2.0K | 69,081 | — | ↗ |
| 2024-06-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 5,055 | 1.29 | 6.5K | 127,751 | — | ↗ |
| 2024-05-17 | WIDDER KENNETH J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2024-05-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,333 | 1.38 | 1.8K | 183,188 | — | ↗ |
| 2024-05-17 | Shoff Lonnie | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2024-05-17 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,731 | 1.38 | 2.4K | 70,666 | — | ↗ |
| 2024-05-17 | MYERS WOODROW A JR | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2024-05-17 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2024-05-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 940 | 1.38 | 1.3K | 132,806 | — | ↗ |
| 2024-05-17 | Bloom Olivia Kyusuk | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2024-05-17 | BOWMAN A BLAINE | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2024-04-30 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 4,523 | 1.37 | 6.2K | 72,397 | — | ↗ |
| 2024-03-15 | Tachibana Aaron | Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 1.61 | 281.8K | 175,000 | — | ↗ |
| 2024-03-15 | Moore Stephen Michael | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 1.61 | 161.0K | 100,000 | — | ↗ |
| 2024-03-15 | Hall Christopher M | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 1.61 | 644.0K | 400,000 | — | ↗ |
| 2024-03-15 | Chen Richard | Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 1.61 | 281.8K | 175,000 | — | ↗ |
| 2024-03-01 | MYERS WOODROW A JR | Director | P-Purchase | A | Common Stock | 10,000 | 1.67 | 16.7K | 26,116 | — | ↗ |
| 2024-01-29 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 716 | 1.37 | 980.92 | 184,521 | — | ↗ |
| 2024-01-29 | Chen Richard | Officer | S-Sale | D | Common Stock | 526 | 1.37 | 720.62 | 128,870 | — | ↗ |
| 2023-12-15 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 6,747 | 1.47 | 9.9K | 185,237 | — | ↗ |
| 2023-12-15 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,476 | 1.47 | 2.2K | 76,920 | — | ↗ |
| 2023-12-15 | Chen Richard | Officer | S-Sale | D | Common Stock | 4,708 | 1.47 | 6.9K | 129,396 | — | ↗ |
| 2023-11-28 | Tempus Labs, Inc. | 10% Owner | — | D | Warrant (Right to Buy) | 4,609,400 | 2.50 | 11.52M | 0 | — | ↗ |
| 2023-11-28 | LEFKOFSKY ERIC P | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 150,000 | — | ↗ |
| 2023-11-16 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,344 | 1.04 | 1.4K | 191,984 | — | ↗ |
| 2023-11-16 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,722 | 1.04 | 1.8K | 78,396 | — | ↗ |
| 2023-11-16 | Chen Richard | Officer | S-Sale | D | Common Stock | 940 | 1.04 | 977.60 | 124,104 | — | ↗ |
| 2023-11-01 | Hall Christopher M | Director / Officer | S-Sale | D | Common Stock | 20,459 | 0.93 | 19.0K | 204,541 | — | ↗ |
| 2023-07-31 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 662 | 2.26 | 1.5K | 193,328 | — | ↗ |
| 2023-07-31 | Chen Richard | Officer | S-Sale | D | Common Stock | 485 | 2.26 | 1.1K | 125,044 | — | ↗ |
| 2023-06-16 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 6,904 | 2.07 | 14.3K | 193,990 | — | ↗ |
| 2023-06-16 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,509 | 2.07 | 3.1K | 80,118 | — | ↗ |
| 2023-06-16 | Chen Richard | Officer | S-Sale | D | Common Stock | 4,817 | 2.07 | 10.0K | 125,529 | — | ↗ |
| 2023-06-13 | WIDDER KENNETH J | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 2.31 | 184.8K | 80,000 | — | ↗ |
| 2023-05-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,389 | 1.98 | 2.8K | 200,894 | — | ↗ |
| 2023-05-17 | Shoff Lonnie | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 2.07 | 82.8K | 40,000 | — | ↗ |
| 2023-05-17 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,781 | 1.98 | 3.5K | 81,627 | — | ↗ |
| 2023-05-17 | MYERS WOODROW A JR | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 2.07 | 82.8K | 40,000 | — | ↗ |
| 2023-05-17 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 2.07 | 82.8K | 40,000 | — | ↗ |
| 2023-05-17 | Colowick Alan | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 2.07 | 82.8K | 40,000 | — | ↗ |
| 2023-05-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 971 | 1.98 | 1.9K | 130,346 | — | ↗ |
| 2023-05-17 | Bloom Olivia Kyusuk | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 2.07 | 82.8K | 40,000 | — | ↗ |
| 2023-05-17 | BOWMAN A BLAINE | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 2.07 | 82.8K | 40,000 | — | ↗ |
| 2023-05-02 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 5,102 | 2.29 | 11.7K | 83,408 | — | ↗ |
| 2023-03-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 3,945 | 2.83 | 11.2K | 202,283 | — | ↗ |
| 2023-03-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,314 | 2.83 | 3.7K | 131,317 | — | ↗ |
| 2023-03-15 | Tachibana Aaron | Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 2.76 | 1.24M | 450,000 | — | ↗ |
| 2023-03-15 | Moore Stephen Michael | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 2.76 | 110.4K | 40,000 | — | ↗ |
| 2023-03-15 | Hall Christopher M | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 2.76 | 1.10M | 400,000 | — | ↗ |
| 2023-03-15 | Chen Richard | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 2.76 | 690.0K | 250,000 | — | ↗ |
| 2023-01-31 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 767 | 2.20 | 1.7K | 206,228 | — | ↗ |
| 2023-01-31 | Chen Richard | Officer | S-Sale | D | Common Stock | 562 | 2.20 | 1.2K | 132,631 | — | ↗ |
| 2022-12-31 | Hall Christopher M | Officer | — | D | Common Stock | 0 | 0.00 | — | 225,000 | — | ↗ |
| 2022-12-20 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 3,843 | 1.92 | 7.4K | 206,995 | — | ↗ |
| 2022-12-20 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,750 | 1.92 | 3.4K | 133,193 | — | ↗ |
| 2022-12-15 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 7,177 | 2.50 | 17.9K | 210,838 | — | ↗ |
| 2022-12-15 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,930 | 2.50 | 4.8K | 88,510 | — | ↗ |
| 2022-12-15 | Chen Richard | Officer | S-Sale | D | Common Stock | 7,177 | 2.50 | 17.9K | 134,943 | — | ↗ |
| 2022-12-14 | West John Stephen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 239,999 | — | ↗ |
| 2022-12-02 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 4,360 | 2.60 | 11.3K | 218,015 | — | ↗ |
| 2022-12-02 | Chen Richard | Officer | S-Sale | D | Common Stock | 440 | 2.60 | 1.1K | 142,120 | — | ↗ |
| 2022-11-16 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,294 | 2.71 | 3.5K | 222,375 | — | ↗ |
| 2022-11-16 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,295 | 2.71 | 3.5K | 142,560 | — | ↗ |
| 2022-10-31 | Hall Christopher M | Officer | — | D | Stock Option (Right to Buy) | 275,000 | 2.67 | 734.3K | — | — | ↗ |
| 2022-09-20 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 3,474 | 3.48 | 12.1K | 223,669 | — | ↗ |
| 2022-09-02 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 4,168 | 3.33 | 13.9K | 227,143 | — | ↗ |
| 2022-09-02 | Chen Richard | Officer | S-Sale | D | Common Stock | 420 | 3.33 | 1.4K | 145,436 | — | ↗ |
| 2022-08-15 | West John Stephen | Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 0.00 | — | 450,000 | — | ↗ |
| 2022-08-15 | Tachibana Aaron | Officer | A-Award | A | Stock Option (right to buy) | 29,890 | 5.32 | 159.0K | 29,890 | — | ↗ |
| 2022-08-15 | Moore Stephen Michael | Officer | A-Award | A | Common Stock | 18,600 | 0.00 | — | 92,485 | — | ↗ |
| 2022-08-15 | Chen Richard | Officer | A-Award | A | Stock Option (right to buy) | 29,890 | 0.00 | — | 29,890 | — | ↗ |
| 2022-08-02 | Shoff Lonnie | Director | A-Award | A | Common Stock | 30,940 | 0.00 | — | 30,940 | — | ↗ |
| 2022-07-28 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 632 | 3.91 | 2.5K | 231,311 | — | ↗ |
| 2022-07-28 | Chen Richard | Officer | S-Sale | D | Common Stock | 632 | 3.91 | 2.5K | 145,856 | — | ↗ |
| 2022-06-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 3,440 | 3.29 | 11.3K | 231,943 | — | ↗ |
| 2022-06-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,565 | 3.29 | 5.1K | 146,488 | — | ↗ |
| 2022-06-15 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 6,818 | 3.24 | 22.1K | 235,383 | — | ↗ |
| 2022-06-15 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 1,832 | 3.24 | 5.9K | 73,885 | — | ↗ |
| 2022-06-15 | Chen Richard | Officer | S-Sale | D | Common Stock | 6,818 | 3.24 | 22.1K | 148,053 | — | ↗ |
| 2022-06-02 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 4,187 | 3.59 | 15.0K | 242,201 | — | ↗ |
| 2022-06-02 | Chen Richard | Officer | S-Sale | D | Common Stock | 421 | 3.59 | 1.5K | 154,871 | — | ↗ |
| 2022-05-17 | MYERS WOODROW A JR | Director | A-Award | A | Common Stock | 10,770 | 0.00 | — | 16,116 | — | ↗ |
| 2022-05-17 | LUDLUM KEN | Director | A-Award | A | Common Stock | 10,770 | 0.00 | — | 43,506 | — | ↗ |
| 2022-05-17 | EASTHAM KARIN | Director | A-Award | A | Stock Option (right to buy) | 15,035 | 4.81 | 72.3K | 15,035 | — | ↗ |
| 2022-05-17 | Colowick Alan | Director | A-Award | A | Common Stock | 10,770 | 0.00 | — | 13,506 | — | ↗ |
| 2022-05-17 | Bloom Olivia Kyusuk | Director | A-Award | A | Common Stock | 10,770 | 0.00 | — | 21,015 | — | ↗ |
| 2022-05-17 | BOWMAN A BLAINE | Director | A-Award | A | Common Stock | 10,770 | 0.00 | — | 13,506 | — | ↗ |
| 2022-05-16 | West John Stephen | Officer | S-Sale | D | Common Stock | 2,408 | 4.86 | 11.7K | 382,444 | — | ↗ |
| 2022-05-16 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,286 | 4.86 | 6.2K | 246,388 | — | ↗ |
| 2022-05-16 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 664 | 4.86 | 3.2K | 75,717 | — | ↗ |
| 2022-05-16 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,286 | 4.86 | 6.2K | 155,830 | — | ↗ |
| 2022-05-02 | Moore Stephen Michael | Officer | S-Sale | D | Common Stock | 5,733 | 5.53 | 31.7K | 76,381 | — | ↗ |
| 2022-04-20 | West John Stephen | Director / Officer | M-Exempt | A | Common Stock | 45,061 | 1.84 | 82.9K | 384,852 | — | ↗ |
| 2022-04-13 | West John Stephen | Officer | M-Exempt | A | Common Stock | 64,430 | 1.84 | 118.6K | 404,221 | — | ↗ |
| 2022-03-17 | West John Stephen | Officer | D-Return | D | Stock Option (Right to Buy) | 54,347 | 0.00 | — | 0 | — | ↗ |
| 2022-03-17 | Tachibana Aaron | Officer | D-Return | D | Common Stock | 3,767 | 7.98 | 30.1K | 247,674 | — | ↗ |
| 2022-03-17 | Chen Richard | Officer | D-Return | D | Common Stock | 1,776 | 7.98 | 14.2K | 155,558 | — | ↗ |
| 2022-03-15 | West John Stephen | Director / Officer | A-Award | A | Common Stock | 68,162 | 1.84 | 125.4K | 353,619 | — | ↗ |
| 2022-03-14 | West John Stephen | Officer | A-Award | A | Common Stock | 21,206 | 1.84 | 39.0K | 306,663 | — | ↗ |
| 2022-03-11 | West John Stephen | Officer | A-Award | A | Common Stock | 10,888 | 1.84 | 20.0K | 296,339 | — | ↗ |
| 2022-03-10 | West John Stephen | Officer | D-Return | D | Common Stock | 32,897 | 9.38 | 308.6K | 285,457 | — | ↗ |
| 2022-03-03 | Lightspeed Venture Partners Select IV, L.P. | 10% Owner | P-Purchase | A | Common Stock | 4,750 | 10.38 | 49.3K | 4,750 | — | ↗ |
| 2022-03-02 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 4,511 | 10.18 | 45.9K | 251,441 | — | ↗ |
| 2022-03-02 | Nieh Peter | Director | P-Purchase | A | Common Stock | 4,750 | 10.38 | 49.3K | 4,750 | — | ↗ |
| 2022-03-02 | Lightspeed Venture Partners Select IV, L.P. | 10% Owner | P-Purchase | A | Common Stock | 48,989 | 9.96 | 487.9K | 1,823,229 | — | ↗ |
| 2022-03-02 | Chen Richard | Officer | S-Sale | D | Common Stock | 471 | 10.18 | 4.8K | 157,334 | — | ↗ |
| 2022-03-01 | Bloom Olivia Kyusuk | Director | A-Award | A | Stock Option (Right to Buy) | 15,691 | 0.00 | — | 15,691 | — | ↗ |
| 2022-02-17 | Moore Stephen Michael | Officer | — | D | Common Stock | 0 | 0.00 | — | 11,475 | — | ↗ |
| 2022-01-28 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 705 | 9.93 | 7.0K | 255,952 | — | ↗ |
| 2022-01-28 | Chen Richard | Officer | S-Sale | D | Common Stock | 705 | 9.93 | 7.0K | 157,805 | — | ↗ |
| 2022-01-19 | West John Stephen | Director / Officer | S-Sale | D | Common Stock | 64,503 | 11.01 | 710.2K | 285,457 | — | ↗ |
| 2022-01-18 | West John Stephen | Director / Officer | S-Sale | D | Common Stock | 35,484 | 11.73 | 416.2K | 349,960 | — | ↗ |
| 2021-12-17 | West John Stephen | Director / Officer | S-Sale | D | Common Stock | 2,732 | 12.80 | 35.0K | 385,444 | — | ↗ |
| 2021-12-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 3,437 | 12.80 | 44.0K | 256,657 | — | ↗ |
| 2021-12-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,563 | 12.80 | 20.0K | 158,510 | — | ↗ |
| 2021-12-16 | West John Stephen | Director / Officer | S-Sale | D | Common Stock | 97,268 | 13.42 | 1.31M | 388,176 | — | ↗ |
| 2021-12-14 | Tachibana Aaron | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 260,094 | — | ↗ |
| 2021-12-14 | Chen Richard | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 160,073 | — | ↗ |
| 2021-12-02 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 4,184 | 12.92 | 54.1K | 180,094 | — | ↗ |
| 2021-12-02 | Chen Richard | Officer | S-Sale | D | Common Stock | 419 | 12.92 | 5.4K | 80,073 | — | ↗ |
| 2021-11-30 | West John Stephen | Director / Officer | S-Sale | D | Common Stock | 100,000 | 13.65 | 1.37M | 485,444 | — | ↗ |
| 2021-11-17 | West John Stephen | Director / Officer | S-Sale | D | Common Stock | 2,348 | 17.04 | 40.0K | 585,444 | — | ↗ |
| 2021-11-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 1,253 | 17.04 | 21.4K | 184,278 | — | ↗ |
| 2021-11-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,253 | 17.04 | 21.4K | 79,781 | — | ↗ |
| 2021-10-29 | Chen Richard | Officer | A-Award | A | Common Stock | 711 | 16.68 | 11.9K | 80,492 | — | ↗ |
| 2021-10-12 | West John Stephen | Director / Officer | S-Sale | D | Common Stock | 100,000 | 19.33 | 1.93M | 587,792 | — | ↗ |
| 2021-09-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 3,152 | 21.25 | 67.0K | 185,531 | — | ↗ |
| 2021-09-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,088 | 21.25 | 23.1K | 81,034 | — | ↗ |
| 2021-09-14 | West John Stephen | Director / Officer | D-Return | D | Common Stock | 93,400 | 21.65 | 2.02M | 694,392 | — | ↗ |
| 2021-09-02 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 3,820 | 21.92 | 83.7K | 188,683 | — | ↗ |
| 2021-09-02 | Chen Richard | Officer | S-Sale | D | Common Stock | 291 | 21.92 | 6.4K | 82,122 | — | ↗ |
| 2021-08-26 | West John Stephen | Director / Officer | A-Award | A | Common Stock | 77,272 | 0.44 | 34.0K | 787,792 | — | ↗ |
| 2021-08-19 | West John Stephen | Director / Officer | A-Award | A | Common Stock | 115,228 | 0.44 | 50.7K | 825,748 | — | ↗ |
| 2021-08-06 | Chen Richard | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,946 | 0.44 | 2.6K | 0 | — | ↗ |
| 2021-07-27 | Tachibana Aaron | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 20.40 | 255.0K | 12,500 | — | ↗ |
| 2021-07-27 | Chen Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 20.40 | 255.0K | 12,500 | — | ↗ |
| 2021-07-15 | West John Stephen | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.44 | 33.0K | 710,520 | — | ↗ |
| 2021-07-08 | West John Stephen | Director / Officer | A-Award | A | Common Stock | 110,000 | 0.44 | 48.4K | 745,520 | — | ↗ |
| 2021-06-17 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 2,421 | 22.75 | 55.1K | 182,503 | — | ↗ |
| 2021-06-17 | Chen Richard | Officer | S-Sale | D | Common Stock | 1,101 | 22.75 | 25.0K | 74,980 | — | ↗ |
| 2021-06-15 | West John Stephen | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 75,000 | 0.44 | 33.0K | 377,499 | — | ↗ |
| 2021-06-15 | Moore Stephen Michael | Officer | — | D | Stock Option (Right to Buy) | 25,000 | 19.74 | 493.5K | 0 | — | ↗ |
| 2021-06-08 | West John Stephen | Director / Officer | A-Award | D | Common Stock | 110,000 | 0.44 | 48.4K | 670,520 | — | ↗ |
| 2021-06-02 | Tachibana Aaron | Officer | S-Sale | D | Common Stock | 2,899 | 21.57 | 62.5K | 184,924 | — | ↗ |
| 2021-06-02 | Chen Richard | Officer | S-Sale | D | Common Stock | 291 | 21.57 | 6.3K | 76,081 | — | ↗ |
| 2021-05-15 | West John Stephen | Director / Officer | A-Award | A | Stock Option (right to buy) | 107,500 | 19.74 | 2.12M | 107,500 | — | ↗ |
| 2021-05-15 | Tachibana Aaron | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 19.74 | 789.6K | 40,000 | — | ↗ |
| 2021-05-15 | Chen Richard | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 19.74 | 888.3K | 45,000 | — | ↗ |
| 2021-05-14 | MacQuitty Jonathan | Director | A-Award | A | Common Stock | 2,736 | 0.00 | — | 2,736 | — | ↗ |
| 2021-05-14 | MYERS WOODROW A JR | Director | A-Award | A | Stock Option (right to buy) | 4,229 | 19.74 | 83.5K | 4,229 | — | ↗ |
Executive team
Top executives
Shares Outstanding
88.80M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Christopher Hall Chief Executive Officer and Director | 618.0K | — | 853.1K | 1.78M | 247.2K | 3.0K | 3.51M | 75.24% | ↗ |
| 2 | 2025 | Aaron Tachibana Chief Financial Officer and Chief Operating Officer | 545.9K | — | 272.3K | 656.2K | 131.0K | 3.0K | 1.61M | 57.73% | ↗ |
| 3 | 2025 | Richard Chen, M.D., M.S. President, Executive Vice President, Research and Development and Chief Medical Officer | 530.5K | — | 272.3K | 656.2K | 127.3K | 3.0K | 1.59M | 58.42% | ↗ |
| 4 | 2024 | Christopher Hall President, Chief Executive Officer, and Director | 587.5K | — | — | 522.5K | 423.0K | 3.0K | 1.54M | 34.02% | ↗ |
| 5 | 2024 | Christopher Hall Chief Executive Officer and Director | 587.5K | — | — | 522.5K | 423.0K | 3.0K | 1.54M | 34.02% | ↗ |
| 6 | 2024 | Aaron Tachibana Chief Financial Officer and Chief Operating Officer | 526.3K | — | — | 229.7K | 252.6K | 3.0K | 1.01M | 22.71% | ↗ |
| 7 | 2024 | Richard Chen, M.D., M.S. President, Executive Vice President, Research and Development and Chief Medical Officer | 511.3K | — | — | 229.7K | 245.4K | 3.0K | 989.4K | 23.22% | ↗ |
| 8 | 2024 | Richard Chen, M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | 511.3K | — | — | 229.7K | 245.4K | 3.0K | 989.4K | 23.22% | ↗ |
| 9 | 2023 | Christopher Hall President, Chief Executive Officer, and Director | 533.8K | — | — | 763.0K | 427.0K | 3.0K | 1.73M | 44.19% | ↗ |
| 10 | 2023 | Aaron Tachibana Chief Financial Officer, Chief Operating Officer, and former interim Chief Executive Officer | 505.0K | — | — | 858.4K | 303.0K | 3.0K | 1.67M | 51.42% | ↗ |
| 11 | 2023 | Aaron Tachibana Chief Financial Officer and Chief Operating Officer | 505.0K | — | — | 858.4K | 303.0K | 3.0K | 1.67M | 51.42% | ↗ |
| 12 | 2023 | Richard Chen, M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | 498.5K | — | — | 476.9K | 299.1K | 3.0K | 1.28M | 37.33% | ↗ |
| 13 | 2023 | Stephen Moore Chief Legal Officer and Corporate Secretary | 425.0K | — | — | 76.3K | 170.0K | 3.0K | 674.3K | 11.32% | ↗ |
| 14 | 2022 | John West Former President, Chief Executive Officer, and Director | 618.0K | — | 1.61M | 2.57M | — | 822.2K | 5.62M | 74.35% | ↗ |
| 15 | 2022 | Christopher Hall President, Chief Executive Officer, and Director | 82.7K | — | 600.8K | 511.5K | 15.5K | 2.0K | 1.21M | 91.73% | ↗ |
| 16 | 2022 | Richard Chen, M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | 489.3K | — | — | 106.4K | 91.9K | 3.0K | 690.6K | 15.41% | ↗ |
| 17 | 2022 | Stephen Moore Chief Legal Officer and Corporate Secretary | 409.2K | — | 99.0K | 102.2K | 68.3K | 3.0K | 681.7K | 29.50% | ↗ |
| 18 | 2022 | Aaron Tachibana Chief Financial Officer, Chief Operating Officer, and former interim Chief Executive Officer | 468.8K | — | — | 106.4K | 97.9K | 3.0K | 676.0K | 15.74% | ↗ |
| 19 | 2021 | John West President, Chief Executive Officer, and Director | 587.5K | — | 1.06M | 2.68M | 601.6K | 1.5K | 4.93M | 75.85% | ↗ |
| 20 | 2021 | John West Former President, Chief Executive Officer, and Director | 587.5K | — | 1.06M | 2.68M | 601.6K | 1.5K | 4.93M | 75.85% | ↗ |
| 21 | 2021 | Richard Chen, M.D., M.S. Chief Scientific Officer | 468.8K | — | 1.66M | 707.9K | 226.9K | 1.5K | 3.06M | 77.23% | ↗ |
| 22 | 2021 | Richard Chen, M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | 468.8K | — | 1.66M | 707.9K | 222.2K | 1.5K | 3.06M | 77.35% | ↗ |
| 23 | 2021 | Aaron Tachibana Chief Financial Officer, Chief Operating Officer, and former interim Chief Executive Officer | 443.8K | — | 1.66M | 646.6K | 214.8K | 1.5K | 2.96M | 77.72% | ↗ |
| 24 | 2021 | Aaron Tachibana Chief Financial Officer | 443.8K | — | 1.66M | 646.6K | 214.8K | 1.5K | 2.96M | 77.72% | ↗ |
| 25 | 2020 | John West President, Chief Executive Officer, and Director | 537.5K | — | — | 2.35M | 495.0K | 1.0K | 3.38M | 69.45% | ↗ |
| 26 | 2020 | Aaron Tachibana Chief Financial Officer | 412.5K | — | 391.9K | 519.1K | 190.0K | 1.0K | 1.51M | 60.15% | ↗ |
| 27 | 2020 | Richard Chen, M.D., M.S. Chief Scientific Officer | 437.5K | — | 178.1K | 619.8K | 200.0K | 1.0K | 1.44M | 55.55% | ↗ |
| 28 | 2019 | Aaron Tachibana Chief Financial Officer | 292.7K | — | 886.0K | 1.69M | 130.0K | — | 3.00M | 85.93% | ↗ |
| 29 | 2019 | John West President, Chief Executive Officer, and Director | 476.4K | — | — | 196.5K | 309.0K | — | 982.0K | 20.02% | ↗ |
| 30 | 2019 | Richard Chen, M.D., M.S. Chief Scientific Officer | 393.8K | — | 88.6K | — | 150.0K | — | 632.4K | 14.01% | ↗ |
| 31 | 2018 | John West President, Chief Executive Officer, and Director | 421.8K | — | — | 879.5K | 190.3K | — | 1.49M | 58.97% | ↗ |
| 32 | 2018 | Richard Chen, M.D., M.S. Chief Scientific Officer | 370.0K | — | — | 335.9K | — | — | 841.0K | 39.95% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher Hall | CEO & Director | 868.2K | male |
| Aaron L. Tachibana | Chief Financial Officer & Chief Operating Officer | 679.9K | male |
| Richard Chen | Executive Vice President of R&D and Chief Medical Officer | 660.8K | — |
| Stephen Moore | Senior Vice President, Chief Legal Officer & Corporate Secretary | 598.0K | male |
| Deepshikha Bhandari | Senior Vice President of Regulatory, Quality & Clinical Compliance | — | female |
| Euan A. Ashley DPHIL FRCP | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — |
| Michael Snyder | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — |
| Christian Haudenschild | Senior Vice President of Genomic Science | — | — |
| Russ Altman | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — |
| Stephane Mouradian | Senior Vice President of Business Development | — | male |
| Ashish Kheterpal | Senior Vice President & Chief Information Officer | — | male |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PSNL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
